Processing procedures for inducing
domain size reduction and/or
amorphous phase generation can be crucial for enhancing the bioavailability
of active pharmaceutical ingredients (APIs). It is important to quantify
these reduced coherence phases and to detect and characterize associated
structural changes, to ensure that no deleterious effects on safety,
function, or stability occur. Here, X-ray powder diffraction (XRPD),
total scattering pair distribution function (TSPDF) analysis, and
solid-state nuclear magnetic resonance spectroscopy (SSNMR) have been
performed on samples of GSK2838232B, an investigational drug for the
treatment of human immunodeficiency virus (HIV). Preparations were
obtained through different mechanical treatments resulting in varying
extents of domain size reduction and amorphous phase generation. Completely
amorphous formulations could be prepared by milling and microfluidic
injection processes. Microfluidic injection was shown to result in
a different local structure due to dispersion with dichloromethane
(DCM). Implications of combined TSPDF and SSNMR studies to characterize
molecular compounds are also discussed, in particular, the possibility
to obtain a thorough structural understanding of disordered samples
from different processes.